
# Congratulating HMS Most Outstanding HST Preclerkship Course Director Award

## Jason Freed, MD, & Sol Schulman, MD, PhD





**Jason Freed, MD**, and **Sol Schulman, MD, PhD**, have been selected as the recipients of the **2026 Most Outstanding HST Preclerkship Course Director Award** from **Harvard Medical School** in recognition of their work as the course directors for HT080 Hematology. This award is presented to the director or co-directors of an HST preclerkship course who, in the past year, demonstrated the most outstanding excellence in their educational leadership of one of the major curricular elements in the HMS Program in Medical Education. The award is among HMS's most visible commendations of teaching accomplishments and reflects how much the Course Directors are valued by their students and by HMS.

Dr. Freed is the Medical Director of Oncology Informatics for BIDMC and BILH and an Assistant Professor of Medicine at Harvard Medical School. He completed his residency, chief residency, and fellowship training at BIDMC before joining the faculty in 2017, as part of the Division of Hematology and Hematologic Malignancies. He has a number of leadership roles at BIDMC and HMS including serving as the Director of Fellowship Education for the Department of Medicine and as the Founding Director of the BIDMC Clinician Educator Track for Fellows, the first of its kind.

Dr. Schulman is a physician-scientist in the Division of Hemostasis and Thrombosis at BIDMC and Harvard Medical School. His graduate thesis research in the laboratory of Professor Tom Rapoport provided important insights into human vitamin K metabolism and the mechanisms of warfarin resistance. Supported by the NIH Director's Early Independence Award DP5, Dr. Schulman subsequently launched his independent laboratory focused on integrating human genetics, functional genomics, and cell biology to identify new mechanisms that regulate the initiation of blood coagulation. He is particularly interested in understanding genetic modifiers of the tissue factor pathway relevant to human bleeding and thrombotic risk. Dr. Schulman maintains a focused clinical practice in non-malignant hematology with particular expertise in the diagnosis and treatment of patients with rare bleeding and clotting disorders.